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Abstract. Gabapentin, C9H17NO2, 2-[1-(aminomethyl)cyclohexyl]acetic acid, is used as an 
anticonvulsant drug to help control partial seizures in the treatment of epilepsy and to 
manage postherpetic neuralgia after ‘shingles’. Cocrystals of gabapentin with a series of 
hydroxyl carboxylic acids and a cocrystal of gabapentin with oxalic acid were previously 
reported. The adduct with salicylic acid was prepared, along with adducts of two 
dicarboxylic acids, succinic acid and adipic acid, and an adduct with 1,2,4,5-
benzenetetracarboxylic acid. Formation of new materials is demonstrated by new unique 
physical properties, including lower melting points (102.8-105.1 ºC, 90.0-93.0 ºC, and 
152.4-154.8 ºC for succinic acid, adipic acid, and 1,2,4,5-benzenetetracarboxylic acid 
products, respectively) than those of the individual starting materials. Shifts in infrared 
bands for ν(O–H), ν(N–H), and ν(C=O) bands confirm adduct formation and indicate the 
nature of the interactions between the two components in the lattice. 
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1. Introduction 
 
Gabapentin, C9H17NO2, 2-[1-(aminomethyl)cyclohexyl]acetic acid is a drug used as an anticonvulsant to 
help control partial seizures in the treatment of epilepsy. It reduces the number of seizures by increasing the 
amount of a closely related chemical called -aminobutyric acid (GABA) in the brain. It is also used in 
adults to manage a condition called postherpetic neuralgia, the pain that occurs after “shingles”. 
Pharmaceutical cocrystallization is of great interest in the field of drug development. Formation of 
cocrystals of pharmaceutical solids can often improve physicochemical properties, such as solubility, 
stability, bioavailability, hydroscopicity, and compaction behavior [1]. In the simplest sense cocrystals are 
crystalline molecular complexes containing two or more species with essentially molecular properties bound 
together in a single crystal lattice through noncovalent interactions [2-3]. Hydrogen bonds are the basis of 
molecular recognition phenomena in pharmaceutical systems and are responsible for the generation of 
families of periodic molecular networks with only one molecular component (single component crystals 
and their polymorphs) or with multiple molecular components (cocrystals or multiple component crystals, 
including solvates) in the crystalline state. The design of experiments to exploit formation of extended 
networks based on noncovalent interactions is a goal of crystal engineering. 
Gabapentin contains strong hydrogen bond donor and strong hydrogen bond acceptor groups (see Fig. 
1) which makes its participation in such networks possible. Four crystalline forms of gabapentin have been 
reported [4-6], attesting to its flexibility in forming supramolecular structures. Form I is gabapentin 
monohydrate, and Forms II, III, and IV are the α-gabapentin, β-gabapentin, and γ-gabapentin polymorphs, 
respectively. Compounds containing carboxylic acid functional groups can readily interact with the −NH2 
and −COOH fragments of un-ionized gabapentin, or the –NH3+ and –COO
 fragments of Zwitterionic 
gabapentin (Fig. 1) to form network synthons as seen in previous studies with GABA and gabapentin with 
carboxylic acids [7-10]. Melting points of the four known forms of gabapentin are given in Table 1. 
 
 
 
Fig. 1. Structural diagrams of gabapentin and the organic acids used in this study. 
 
 
Cocrystallization of gabapentin with oxalic acid was reported in 2008 [9] and with a series of hydroxyl 
carboxylic acids in 2009 [10]. The 2008 study included a survey of the Cambridge Structural Database,  
CSD that identified over 12,000 instances of the particular bonding pattern as illustrated in Figure 2(a). The 
largest fraction of the CSD hits involves four individual moieties that are not covalently connected. Many 
involve two chemically different species, and thus, are cocrystalline or other multicomponent systems. In 
graph set notation this pattern is designated R42(8), where R identifies it as a ring, a cyclic pattern of bonds, 
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the subscript denotes the number of hydrogen bond donors involved in the set, and the superscript denotes 
the number of hydrogen bond acceptors involved in the set [11]. An individual pattern of such 
supramolecular interactions is often called a synthon (or sometimes a supramolecular synthon), and can be 
understood as a logical extension of the concept of functional group originating in organic chemistry. While 
it is not necessary for a synthon to be symmetric, both synthons illustrated in Fig. 2 are often found in the 
solid state positioned about a crystallographic inversion center or exhibiting pseudo centrosymmety. The 
CSD survey finds 918 hits for structures exhibiting the R42(8) synthon in which the donor is an amino 
group (−NH2) and the acceptor is a carbonyl group (>C=O). Ammonium donor (−NH3+) and carboxylate 
acceptor (−COO−) forms are also well represented in the CSD survey. The gabapentium oxalate report 
itself has an example of a crystallographically centrosymmetric R42(8) synthon involving the ionized forms. 
 
 
Table 1. Melting points of gabapentin polymorphs and gabapentin monohydrate. 
 
Form Species Melting point (C) Reference 
I gabapentin monohydrate 156.0-156.7 [4] 
II α-gabapentin 160.0-162.0, 155.0-166.0 a [5-6] 
III β-gabapentin 156.0-158.0, 155.0-168.0 a [5-6] 
IV γ-Gabapentin 150.0-168.0 a [6] 
     aMelting point measured by DSC [6]. 
 
 
 
 
 
Fig. 2. Graph set notation for two simple synthons relating to carboxylic acids. a) an R42(8) synthon and 
b) the R22(8) synthon as found in a carboxylic acid dimer. D represents a hydrogen bond donor 
and A represents a hydrogen bond acceptor. 
 
 
The present work reports preparation of adducts of gabapentin with two dicarboxylic acids, succinic 
acid and adipic acid, and an adduct with benzene-1,2,4,5-tetracarboxylic acid. Also, another adduct of 
gabapentin with salicylic acid was found while preparing the reported adduct from a modified solvent 
system. Formation of new materials is demonstrated by new unique physical properties, including melting 
points and morphologies. Shifts in infrared bands confirm adduct formation and indicate the nature of the 
interactions between the two components in the lattice. 
 
2. Experimental 
 
2.1. Chemicals and Solvents 
 
Commercial chemicals: adipic acid (Acros Organics 99%, laboratory grade), succinic acid (Carlo Erba 99.5%, 
AR grade), benzene-1,2,4,5-tetracarboxylic acid, pyromellitic acid, (Acros Organics 96%, laboratory grade), 
and salicylic acid (Mallinckrodt, AR grade), methanol (Carlo Erba 99.9%, AR grade), and DI water. 
 
Separation of gabapentin: Dissolve 7.49 g, the content of 20 capsules, of Gabapentin drug (The Government 
Pharmaceutical Organization, Thailand, 300 mg gabapentin/capsule) in 400 mL of methanol:H2O (3:1 v/v) 
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and warm at 40 ºC with stirring (400 rpm) for 40 min. Filter the hot solution and rinse the solids with cold 
DI water. Heat the filtrate at 50 ºC until the volume is reduced to 130 mL. Cool and let stand at room 
temperature for 3 days to crystallize. The colorless crystals were separated by vacuum filtration on a 
Buchner funnel and washed with 1 mL of cold DI water giving 5.10 g of gabapentin monohydrate (77% 
recovery). 
 
2.2. Cocrystallization 
 
Gabapentin monohydrate (378 mg, 2 mmol) and adipic acid (146 mg, 1 mmol) were ground together 10 
min, dissolved in 5 mL of methanol:H2O (2:1 v/v), and warmed at 37 ºC 20 min with stirring, reducing the 
volume to 2.5 mL. Crystalline product was obtained after 5 weeks of controlled evaporation at room 
temperature. Similar methodology was used for reactions of 2:1 mole ratio gabapentin with succinic acid, of 
1:1 mole ratio gabapentin with benzene-1,2,4,5-tetracarboxylic acid, and of 1:1 mole ratio gabapentin with 
salicylic acid. 
 
2.3. Characterizations 
 
Crystal morphologies were observed with scanning electron microscopy (SEM) using a JSM 6400 electron 
microscope (JEOL, Japan). Infrared (IR) spectra were acquired on a Perkin-Elmer model spectrum GX 
Fourier transform infrared spectrophotometer in wave number range 400-4000 cm−1 from KBr pellets. 
Melting points were measured with a Stuart Model SMP 30 melting point apparatus (Bibby Scientific, UK). 
 
3. Results and Discussion 
 
Gabapentin was separated from commercially available drug capsules with high recovery using a 
methanol:H2O mixed-solvent system. Gabapentin crystals show rectangular crystal morphology as shown 
in Fig. 3. The product was characterized by melting point and IR spectroscopy. The measured melting 
point is 154.0-155.6 C, which corresponds to the melting point of gabapentin monohydrate (Table 1, 
Form I) as well as to that of β-gabapentin (Form III). 
 
 
Fig. 3. SEM image of gabapentin crystal. 
 
 
The infrared spectrum of the crystalline product is presented in Fig. 4. The N−H stretching band, (N-
H), appears at 3286 cm1 and the bending bands, as(N-H) and s(N-H), at 1615 cm
1 and 1544 cm1, 
respectively. A (N-H) band at 2144 cm1 corresponds to the additional vibrational band that often appears 
at about 2100 cm1 when amine is converted to ammonium. Further, the (C=O) band is shifted lower at 
1662 cm1, compared to the typical (C=O) vibration of a carboxylic acid (1700-1730 cm1), consistent 
with the partial delocalization that often occurs in a carboxylate ion. The (CO) band of carboxylate 
shows at 1400 cm1. The band at 3389 cm1 is assigned to (OH) of water, suggesting the product is 
gabapentin monohydrate. The total spectrum is quite similar to gabapentin form I reported in the previous 
work [12], confirming the product to be gabapentin monohydrate. 
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Fig. 4. IR spectrum of gabapentin monohydrate. 
 
 
Morphologies of the solid products of the cocrystallization experiments, observed with SEM, are 
shown in Fig. 5. SEM images of adducts of gabapentin with adipic acid, succinic acid, and benzene-1,2,4,5-
tetracarboxylic acid (Fig. 5(a-c)) show plate morphology while the crystalline product for the adduct of 
gabapentin with salicylic acid shows prism morphology. 
 
 
 
Fig. 5. SEM images of adducts of gabapentin with (a) adipic acid, (b) succinic acid, (c) benzene-1,2,4,5-
tetracarboxylic acid, and (d) salicylic acid. 
 
 
Formation of new materials is demonstrated by new unique physical properties, including lower 
melting points than the starting materials (Table 2). The melting points of the solid product adducts of 
gabapentin with succinic acid and with salicylic acid are quite similar and very much reduced, similar to the 
adduct with malic acid [10]. The melting point of the solid product from reaction of gabapentin with 
salicylic acid is lower (about 30 ºC) than the 131 ºC previously reported [10]. The narrow range of the 
current melting point determination suggests it is indeed a pure compound, and thus is a new adduct of 
gabapentin with salicylic acid. 
Infrared spectra of the adducts were compared to the spectra of both gabapentin and the relevant 
carboxylic acid starting materials to determine the identity of the solids isolated from the cocrystallization 
experiments. The band positions and assignments for the solid products are summarized in Table 3. 
The IR result for the gabapentin:salicylic acid adduct is consistent with the previous report [10], but 
shows new peaks at 1670-1690 cm–1 and 1633 cm–1 when compared to the previous work. These two peaks 
are assigned to (C=O) of carboxylate group and (N–H) of ammonium ion, respectively. 
 (a)   (b)  
(c)  (d)  
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Table 2. Melting points of reactants and multicomponent crystalline products.  
 
 Material Melting point (ºC) 
reactants gabapentin 154.0-155.6 
adipic acid 152.0 
succinic acid 185.0 
benzene-1,2,4,5-tetracarboxylic acid 281.0 
salicylic acid 159.0 
  
adducts gabapentin:adipic acid 90.0-93.0 
gabapentin:succinic acid 102.8-105.1 
gabapentin:benzene-1,2,4,5-tetracarboxylic acid 152.4-154.8 
gabapentin:salicylic acid 102.0-105.0 
 
 
Gabapentin:adipic acid adduct: The IR spectrum contains peaks due to both reactant species. Peaks at 2930 and 
2859 cm–1 are assigned to the (C–H) of gabapentin. The (N–H) band of gabapentin is shifted to lower 
energy (3229 cm–1, Δυ(N–H) = 57 cm–1) indicating the –NH3+···O– interaction of the ionized ammonium of 
gabapentin with a carboxylate group. The (C=O) of a carboxylic acid group at 1702 cm–1 is shifted to 
higher energy compared to both reactants, indicating an –O–H···O– interaction of the carboxylic acid 
group of gabapentin with a carboxylate of adipic acid with the possiblity that an R42(8) hydrogen bond 
synthon has formed. The band at 1645 cm–1 corresponds to (C=O) of carboxylate groups. While similar 
discussion of 2:1 gabapentin:oxalic acid adducts has been reported [9], the possibility of formation does not 
prove the synthon has formed as is illustrated by the GABA:oxalic acid study [7, 8] which contains the 
ionized ammonium and carboxylate forms, but does not contain the R42(8) hydrogen bond synthon. 
 
Gabapentin:succinic acid adduct: The IR spectrum shows peaks at 2935 and 2859 cm–1 due to (C–H) and 
peaks at 1714 and 1644 cm–1 attributed to (C=O) of carboxylic acid and carboxylate, respectively. The 
(N–H) band was observed as a weak broad band at 3258 cm–1, shifted 51 cm–1 to lower energy when 
compared to the gabapentin spectrum, indicating an –NH3+···O– interaction of the ionized ammonium of 
gabapentin with a carboxylate of succinic acid. The (C=O) peak shifted to higher energy at 1725 cm–1 
when compared to the succinic acid spectrum, similar to (C=O) in the gabapentin:adipic acid adduct 
suggesting similar formation of hydrogen bond synthons in the structures. 
 
Gabapentin:benzene-1,2,4,5-tetracarboxylic acid adduct: The (O–H) bands at 3532 and 3389 cm–1 are observed in 
the product spectrum with no peak shift compared to the benzene-1,2,4,5-tetracarboxylic acid spectrum, 
suggesting the carboxylic acid groups do not change to the carboxylate form. There are two (C=O) bands 
at 1690-1712 cm–1 region indicating different types of hydrogen bond formation between the carboxylic 
acid groups of benzene-1,2,4,5-tetracarboxylic acid with Zwitterionic gabapentin. Vibrational bands at 1590 
and 1626 cm–1 are assigned to (N–H) of the ionic –NH3+ and (C=O) of carboxylate, respectively. Similar 
discussion of 1:1 gabapentin:trimesic acid adducts has been previously reported [13]. 
 
Gabapentin:salicylic acid adduct: The (N–H) band at 3253 cm–1 is shifted 33 cm–1  to lower energy compared 
to free gabapentin. A very broad peak in the 3300-2700 cm–1 region indicates hydrogen bond interactions 
between the –NH3+ group of gabapentin and a –COO– carboxylate group. Two (C=O) peaks at 1677 and 
1713 cm–1 shifted to higher frequencies compared to the reactants indicates that the carbonyl group is 
involved in hydrogen bond interaction(s). A previous report on a 1:1 adduct of gabapentin and salicylic acid 
[10] shows intramolecular interaction between –O–H and a carboxylate group in salicylic acid, and 
intermolecular –NH3+···O– interactions between ionized ammonium of gabapentin with the carboxylate 
group of ionized salicylic acid. The solid product from the previous work shows a significantly higher 
melting point than the product of this work. The current product also shows additional peaks at 1670-1690 
cm–1 and 1633 cm–1 in the IR spectrum. These two peaks are assigned to (C=O) of carboxylate group and 
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(N–H) of ionized ammonium, respectively. These results indicate the formation of a new 
gabapentin:salicylic acid adduct. 
 
Table 3. IR spectral peak positions and assignment of gabapentin monohydrate and solid product peaks. 
 
Gabapentin 
Adduct of gabapentin with acid  
Assignment Adipic 
acid 
Succinic acid Benzene-1,2,4,5-
tetracarboxylic 
acid 
Salicylic 
acid 
3389 sh  3481 vw 3532 w, sp 
 
 υ(O–H) 
(3600-3200 cm–1) 
3386 m, br 
 
3229 m 3358 sh 
3235 vw 
3389 sh  
3055 vw 
3253 w 
 
υ(N–H) 
(3500-3100 cm–1) 
2922 s, sp 
2861 m, sp 
2716 vw 
2609 w 
 
2930 s, sp 
2860 m, sp 
2668 vw 
2540 vw 
1926 br 
2935 vs, sp 
2859 m, sp  
2589 w 
2505 sh 
 
2934 m 
2866 w 
2646 vw 
2508 vw 
2928 s 
2861 m 
2708 vw 
2505 vw 
 
υ(C–H) aliphatic 
(3100-2600 cm–1) 
2145 m     υ(N–H) ammonium 
(near 2100 cm–1) 
1663 w 
1615 s, sp 
1702 vs, sp 
1645 s, sp 
1715 vs, sp 
1645 vw 
 
1713 sh 
1693 s 
1714 w, sp 
1677 m, sp 
υ(C=O) carboxylic 
(1730-1700 cm–1) 
υ(C=O) carboxylate 
(asymmetric, 1600 cm–1) 
1544 vs, sp     (N–H) 
(1640-1550 cm–1) 
1474 m, sp 
1455 m, sp 
1420 m, sp 
1400 vs, sp 
1568 s, sp 
1488 s, sp 
1465 w, sp 
1530 vs  
1456 m, sp 
1404 m, sp 
1626 w 
1592 sh 
1487 m 
1443 sh 
1413 m, sp 
1632 vw 
1594 m, sp 
1556 w 
1513 w 
1483 vs, sp 
1454 s, sp 
combination of 
υ(C=C), δ(O–H) 
(1650-1450 cm–1), and 
υ(C=O) carboxylate 
(symmetric, 1400 cm–1) 
1326 w, sp 
1300 vs, sp 
1260 w 
1209 vw 
1196 w, sp 
1165 m, sp 
1119 w, sp 
1082 s, sp 
1020 s, sp 
976 m, sp 
927 m, sp 
890 m, sp 
850 m, sp 
708 vs, sp 
647 w, sp 
627 w, sp 
617 w, sp 
589 w, sp 
508 vw, sp 
1368 w, sp 
1314 w 
1276 vs, sp 
1232 w, sp 
1190 vs, sp 
1125 m, sp 
1079 m, sp 
1059 w, sp 
982 m, sp 
909 m, sp 
850 w, sp 
800 w, sp 
762 w 
708 vs, sp 
625 m, sp 
523 m, sp 
 
1321 s 
1305 s 
1213 w 
1177 vs, sp 
1127 w 
1085 w, sp 
1057 vw, sp 
999 m, sp 
950 w 
883 w 
798 w, sp 
775 w, sp 
740 w, sp 
696 vw 
633 m, sp 
608 m, sp 
597 w 
1369 vw, sp  
1340 w, sp 
1305 w, sp 
1268 vs 
1222 vw 
1196 vw 
1116 m, sp 
1053 w 
957 m 
921 m 
889 m 
865 vw 
814 s, sp 
754 m, sp 
693 w 
646 w 
579 w, sp 
511 w, sp 
 
1390 m, sp 
1357 w 
1327 vw 
1305 m, sp 
1252 s 
1220 vw 
1201 w, sp 
1175 m 
1157 vw 
1140 w, sp 
1087 w, sp 
1029 m, sp 
974 vw 
926 w 
859 m, sp 
805 m, sp 
758 vs, sp 
702 s, sp 
669 s, sp 
536 m, sp 
504 w, sp 
Combination of 
(C–O), (C–N), (C–C) 
(1350-900 cm–1) and  
(C–O) carboxylic 
(1320-1210 cm–1) 
 
Abbreviations: vs = very strong, s = strong, m = medium, w = weak, vw = very weak, sh = shoulder, sp = sharp, br = 
broad; υ = stretching and δ = bending. 
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4. Conclusion 
 
Pure gabapentin was separated from the drug Neurontin with high recovery, 85 % based on the quantity of 
gabapentin in a capsule. Three new solid state molecular complexes; 2:1 gabapentin:adipic acid, 2:1 
gabapentin:succinic acid, and gabapentin:benzene-1,2,4,5-tetracarboxylic acid adduct were formed. The 
product combining gabapentin with salicylic acid shows a lower melting point than the adduct reported in 
published work. Shifts of infrared bands and lower melting points compared to the individual starting 
materials indicate adduct formation and the nature of the interactions between the two components in the 
lattice. 
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